Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Evoke Pharma, Inc. (Nasdaq: EVOK) has announced plans to release its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results. Evoke is focused on developing treatments for gastrointestinal disorders, notably GIMOTI, a nasal spray for diabetic gastroparesis. This condition affects millions and can delay gastric emptying, leading to significant GI symptoms. The company emphasizes that some statements are forward-looking and subject to risks.
- Evoke is poised to report its Q4 and full-year financial results, potentially signaling business performance.
- The focus on GIMOTI addresses a significant market need for diabetic gastroparesis treatment.
- No specific financial performance details or guidance were provided, leaving investors without crucial information.
SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the market closes.
Evoke will host a conference call on Thursday, March 11, 2021, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (877) 473-1186 for domestic callers and (918) 922-6138 for international callers. The conference ID number is 4193567.
In addition, a telephonic replay of the call will be available until March 18, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 4193567.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s anticipated use of proceeds from the offering. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contact:
The Ruth Group
James Salierno
Tel: 973-255-8361
jsalierno@theruthgroup.com
Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com
FAQ
When will Evoke Pharma announce its fourth quarter and full year 2020 financial results?
What is GIMOTI and how does it relate to Evoke Pharma?
How can I participate in Evoke Pharma's conference call?
What risks does Evoke Pharma mention in their press release?
What is diabetic gastroparesis?
